Prelude Therapeutics Q2 net loss narrows to $13.9 million; cash runway into 2028
Prelude Therapeutics reported results for the three months ended June 30, 2026, with a net loss of $13.9 million, or $0.14 per share, down from $31.2 million, or $0.41 per share, a year earlier. The company recorded $5.7 million of revenue, compared with none in the prior-year period, and cash, cash equivalents, restricted cash and marketable securities totaled $155.2 million, which it expects to fund operations into the second quarter of 2028.
Key points
- Net loss was $13.9 million, or $0.14 per share, versus $31.2 million, or $0.41 per share, in Q2 2025.
- Revenue was $5.7 million, compared with none in the prior-year quarter.
- R&D expense fell to $16.1 million from $25.8 million, and G&A expense fell to $5.0 million from $6.4 million.
- The company expects to start the Phase 1 study of PRT13722 in HR+ breast cancer in the fourth quarter of 2026, pending IND clearance.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.